rss
Arch Dis Child Fetal Neonatal Ed 2000;82:F173-F175 doi:10.1136/fn.82.3.F173
  • Leading article

Management of severe alloimmune thrombocytopenia in the newborn

  1. W H OUWEHAND,
  2. G SMITH,
  3. E RANASINGHE
  1. Division of Transfusion Medicine, University of Cambridge and National Blood Service, Cambridge CB2 2PT, UK
  1. Dr Ouwehand

    Petechiae or echymoses and severe thrombocytopenia (< 20 × 109 platelets/litre) is a worrying and serious condition in newborn infants. Rapid correction of the platelet count is essential to prevent cerebral bleeding and associated life long disability, and this should be combined with laboratory investigations to confirm the clinical diagnosis. Prospective studies have revealed that the most likely cause of severe thrombocytopenia in a term and otherwise healthy neonate is immune mediated destruction of fetal/neonatal platelets by maternal alloantibodies.1 2Antibodies can be formed against human platelet alloantigens (HPAs)3 4 present on fetal but not maternal platelets (table 1). Leakage of fetal platelets and possibly other HPA alloantigen expressing fetal cells5 into the maternal circulation during pregnancy can stimulate the mother's immune system to produce IgG alloantibodies against “non-self” HPAs inherited from the father. Maternal HPA alloantibodies of the IgG class cross the placenta and bind to fetal platelets, shortening their survival.

    View this table:
    Table 1

    Clinically most relevant human platelet alloantigen (HPA) systems associated with neonatal alloimmune thrombocytopenia

    Is neonatal alloimmune thrombocytopenia a rare disease?

    Neonatal alloimmune thrombocytopenia is the platelet homologue of haemolytic disease of the newborn and was initially thought to be a rare disease. However, a recent prospective screening study in 25 000 non-selected pregnant women showed an incidence of severe thrombocytopenia (< 50 × 109 platelets/litre) caused by anti-HPA-1a antibodies (see below) of one in 1100 (95% confidence interval, 684 to 2910).6 No antenatal screening procedure is in place to identify women at risk of HPA alloimmunisation because it has not been proved that this would significantly reduce morbidity and mortality.6 Thus, neonatal alloimmune thrombocytopenia is diagnosed in utero if a pregnancy is complicated (for example, cerebral bleeds, hydrocephalus,7 8 or hydrops fetalis) or in the newborn by obvious signs of bleeding or abnormal neurological features pointing towards a possible cerebral bleed.3 4Infrequently, …

    Responses to this article

    Latest from Education & Practice

    Latest from Education & Practice

    Register for free content

    Free sample
    This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ADC Fetal & Neonatal.
    View free sample issue >>

    Free archive
    The full back archive is now available for ADC Fetal & Neonatal. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
    Register to access the free archive >>

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

  • Paediatrics and Paediatric Surgery Jobs

    Paediatrics and Paediatric Surgery Jobs